AzTrials
AzTrials

Transesophageal EchocardiographyNCT03117673

Estimation of Pulmonary Arterial Pressure With Transesophageal Echocardiography: a Pilot Study

An observational study of Transesophageal Echocardiography, run by Medical University of Vienna at 1 site in Austria.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Transesophageal echocardiography (TEE) plays an important role in intraoperative monitoring and can be used to estimate pulmonary artery pressures. An excellent correlation between right ventricular systolic pressure (RVSP) measured by right heart catheterization (RHC) and simultaneously estimated by transthoracic… Read more about this study

Who is it for?
Ages 18 to 99 years
Conditions the study is for
Transesophageal Echocardiography
What is being tested?
transesophageal echocardiography measurements
How many people
39 participants
Where
1 siteAustria
Study dates
1 May 2017to 31 Dec 2020
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 99 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: 39 patients scheduled for cardiac operation in general anaesthesia divided in 3 groups (13 per group): I. Patients with mild to moderate TI and normal RVSP (< 40mmHg) and mean PAP (< 25mmHg) II. Patients with mild to moderate TI and elevated RVSP (> 40mmHg) and mean PAP (> 25mmHg) Patients with severe TI (defined as Vena contracta > or equal 7mm, reversed systolic hepatic vein flow, proximal isovelocity surface area (PISA) radius > 9 mm, and very large central jet or eccentric wall impinging jet)

Who may be able to join

  • Elective cardiac surgery in general anaesthesia
  • Transesophageal echocardiography (TEE) indicated
  • Pulmonary artery catheter (PAC) indicated

Who cannot join

  • Age < 18 years
  • Atrial fibrillation
  • Declined informed consent

Trial locations and contacts

1 site in 1 country.

Austria1 site, 1 recruiting
  • Medical university of vienna, General hospital of Vienna

    Vienna, 1090

    Ulrike Weber, M.D., +43 6766038002, ulrike.weber@meduniwien.ac.at

    Ulrike Weber, M.D.

    Recruiting

Other trials in Austria

About this study

Transesophageal echocardiography (TEE) plays an important role in intraoperative monitoring and can be used to estimate pulmonary artery pressures. An excellent correlation between right ventricular systolic pressure (RVSP) measured by right heart catheterization (RHC) and simultaneously estimated by transthoracic echocardiography is reported and also implemented into the current guidelines for the echocardiographic assessment of the right heart in adults by the American Society of Echocardiography. So far there are no studies evaluating RVSP measured by transesophageal echocardiography (TEE) and recommendations are unclear which transesophageal view is the best for calculation.

We want to assess if there is a difference in the systolic pulmonary artery pressure measured invasively with a pulmonary artery catheter (PAC) and the calculated right ventricular systolic pressure (RVSP) using transesophageal echocardiography (TEE) in 3 different views: ME 4Ch, ME RV inflow-outflow, ME modified bicaval.

Read the detailed description

Transesophageal echocardiography (TEE) plays an important role in intraoperative monitoring and can be used to estimate pulmonary artery pressures. In 1984 Yock et al. were the first ones who reported an excellent correlation between right ventricular systolic pressure (RVSP) measured by right heart catheterization (RHC) and simultaneously estimated by transthoracic echocardiography. Later this was confirmed by several authors (3-6) and therefore also implemented into the current guidelines for the echocardiographic assessment of the right heart in adults by the American Society of Echocardiography. So far there are no studies evaluating RVSP measured by transesophageal echocardiography (TEE) and recommendations are unclear which transesophageal view is the best for calculation. More recent studies evaluated the accuracy of echocardiography in patients with pulmonary hypertension and mostly revealed only a moderate to weak correlation between echocardiography and right heart catheter mesurements. One study evaluated patients with severe tricuspid regurgitation and pulmonary hypertension and showed that pulmonary artery systolic pressure is frequently overestimated in this population. Fewer studies reported a good correlation between these two methods. There is also evidence that additional indices and paramenters can help to assess pulmonry hypertension more precisely with echocardiography, such as TAPSE, Tei index or LV eccentric index. These parameters seem to be abnormal in presence of pulmonary hypertension.

Study objectives (Hypothesis)

We want to assess if there is a difference in the systolic pulmonary artery pressure measured invasively with a pulmonary artery catheter (PAC) and the calculated right ventricular systolic pressure (RVSP) using transesophageal echocardiography (TEE) in 3 different views: ME 4Ch, ME RV inflow-outflow, ME modified bicaval.

Study design

Prospective, single-center, observer-blinded, diagnostic test accuracy study.

Study population

39 patients scheduled for cardiac operation in general anaesthesia divided in 3 groups (13 per group): I. Patients with mild to moderate TI and normal RVSP (< 40mmHg) and mean PAP (< 25mmHg) (22) II. Patients with mild to moderate TI and elevated RVSP (> 40mmHg) and mean PAP (> 25mmHg) (22) III. Patients with severe TI (defined as Vena contracta > or equal 7mm, reversed systolic hepatic vein flow, proximal isovelocity surface area (PISA) radius > 9 mm, and very large central jet or eccentric wall impinging jet) (1, 3)

Patients will undergo informed consent the day before surgery by one physician of the study group.

After introduction of Anaesthesia and insertion of the central lines and the transesophageal echo probe we will start with a standard examination. All study measurements will be done during the standard transesophageal echocardiography (TEE) examination. Therefore, none of the study procedures will interrupt or delay the operation or put the patients into any additional risks.

We measure blood pressure, central venous pressure, pulmonary artery pressure and pulmonary wedge pressure invasively via the inserted central lines. At the same time we do echocardiographic measurements:

The right ventricular systolic pressure (RVSP) is calculated using the modified Bernoulli equation RVSP = 4 x (MaxTRvelocity)2 + RAP. Maximal TR velocity is measured using continuous wave (CW) Doppler. Windows used to measure the maximal TR velocity are the ME 4 chamber view, the ME RV inflow-outflow view and the ME modified bicaval view. TR signal quality is classified in every window according to envelope visibility as good (complete envelope), moderate (partial envelope but prone to extrapolation) or poor (unreliable envelope or no signal). TR severity is assessed as absent, mild, moderate or severe according to the American Society of Echocardiography guidelines. Therefore we measure the paramenters vena contracta, PISA and hepatic venous flow. A predefined value of RVSP > 40mmHg or mean PAP > 25mmHg is considered elevated. We also measure TAPSE, RV Tei Index and LV eccentric index for assessment of pulmonary hypertension. During the whole TEE examination the examiner will be blinded to the pulmonary artery pressure measured by the pulmonary artery catheter. This will be done by a patch that covers just the pulmonary artery measurement on the OR monitor during the TEE examination. After the examination is done the patch will be removed. A study nurse writes down all hemodynamic measurements during the TEE examination.

All measurements will be done after induction of anaesthesia, before start of surgery and also after surgery during skin closure when the patient is still asleep in the OR.

Statistics

The primary outcome of the study is the bias and precision of calculated RVSP with TEE compared to measured systolic pulmonary artery pressure with PAC. The current literature provides no information on possible differences in bias and precision of the measurement between patients with normal, and elevated mean PAP, and those with severe TI, so our sample size considerations are based on the whole cohort. Based on currently published RVSP-distributions to show a clinical significant difference of more than 10% with a power of 80% we will have to include 33 patients in total. This estimation is based on a one-tailed comparison and a probability of error of first kind of 0.05, and was calculated using G*Power 3.1.9.2. To allow for dropouts and uncertainty in this calculation, we will include 39 patients in total. Based on clinical considerations and feasibility, this will include 13 with mild to moderate TI and normal mean PAP, 13 with mild to moderate TI and elevated mean PAP, and 13 with severe TI.

All data will be tabulated case-wise and pair-wise (i.e. PAC and TEE measurements) Quantitative data will be expressed as mean +/- SD if normally distributed or as medians and interquartile ranges (IQRs) if not normally distributed. Qualitative variables will be presented as absolute and relative frequencies. Measurement from the best obtainable of the three TEE views will be used for analysis. According to the method described by Bland and Altman we will assess agreement between measurements: The mean difference (bias, d) as a metric for the systematic measurement error, the SD of the differences (precision, s), and the limits of agreement (d±2s) as metrics for scatter will be calculated. Bland-Altman plots will be used for graphical representation.

For primary analysis, the whole cohort will be used. For secondary analysis, patients with normal, and elevated mean PAP, and those with severe TI will be analyzed separately. Differences between TR signal quality and of RVSP calculations between the three TEE views will be analyzed accordingly.

Statistical analysis will be performed using Stata 12 for Windows (Stata Corp, College Station, TX).

Being tested
transesophageal echocardiography measurements
Keywords
right ventricular systolic pressure (RVSP), Transesophageal echocardiography

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • transesophageal echocardiography measurementsOther

    transesophageal echocardiography will be done routinely during the procedure. We will do additional measurements of the maximal TR velocity

Study groups in NCT03117673
Study groupRoleWhat they receive
group 1Patients with mild to moderate TI and normal RVSP (< 40mmHg) and mean PAP (< 25mmHg)
Receives: Other: transesophageal echocardiography measurements
group 2Patients with mild to moderate TI and elevated RVSP (> 40mmHg) and mean PAP (> 25mmHg)
Receives: Other: transesophageal echocardiography measurements
group 3Patients with severe TI (defined as Vena contracta > or equal 7mm, reversed systolic hepatic vein flow, proximal isovelocity surface area (PISA) radius > 9 mm, and very large central jet or eccentric wall impinging jet)
Receives: Other: transesophageal echocardiography measurements

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. RVSP calculated from TEE measurements

    Bias and precision of RVSP calculated from TEE measurements as compared to measured systolic pulmonary artery pressure with PAC

    Measured: during routine transesophageal echocardiography examination

Secondary outcomes (1)
  1. Differences in bias and precision between patients with normal, and elevated mean PAP, and those with severe TI

    Differences in bias and precision between patients with normal, and elevated mean PAP, and those with severe TI

    Measured: during routine transesophageal echocardiography examination

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted18 Apr 2017
  2. Study start1 May 2017
  3. Primary completion31 Dec 2019 (estimated)
  4. Study completion31 Dec 2020 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case only
Time perspective
Prospective
Enrolment
39 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03117673
Sponsor's protocol ID
1113/2017
Status last verified
Oct 2017
First submitted
6 Apr 2017
Last updated
20 Oct 2017
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Transesophageal Echocardiography, run by Medical University of Vienna at 1 site in Austria.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 20 Oct 2017. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Austria. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Ulrike Weber, MD (004340400 ext. 2516, ulrike.weber@meduniwien.ac.at), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

RVSP calculated from TEE measurements (time frame: during routine transesophageal echocardiography examination). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Oct 2017.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in